$822.83▼ 10.73 (1.29%)
Real-time prices · US MarketsClean balance sheet with low leverage (0.1× debt-to-equity).
Quality
8.5
Health
9.7
Growth
7.3
Valuation
5.9
Sentiment
6.9
Analyst Target
$840.43
▲ +2.1% from current
Price Chart
Latest News
Fundamentals
Trailing P/E
20.4×
price-to-earnings
Forward P/E
13.6×
next 12 months est.
Market Cap
$84.7B
market capitalization
Div Yield
0.45%
dividend yield
Profit Margin
27.9%
net profit margin
Gross Margin
44.5%
revenue minus COGS
ROE
14.0%
return on equity
Beta
0.19
vs S&P 500
52-Week Range
$541 — $847
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
What do analysts say about Regeneron Pharmaceuticals, Inc. right now?
Regeneron Pharmaceuticals, Inc.'s Q·Score is 7.7/10 (Bullish), reflecting its current fundamentals, analyst data, and valuation metrics. Clean balance sheet with low leverage (0.1× debt-to-equity). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for REGN?
The consensus price target for REGN is $840.43, based on ratings from 27 Wall Street analysts. This is 2.1% above the current price of $822.83. Price targets are forward-looking estimates and not guarantees of future performance.
Is REGN overvalued or undervalued?
Regeneron Pharmaceuticals, Inc. (REGN) scores in line with sector averages on valuation metrics. Its forward P/E ratio stands at 13.6×.
When does Regeneron Pharmaceuticals, Inc. report its next earnings?
Regeneron Pharmaceuticals, Inc.'s next earnings report is expected on approximately October 28, 2026.
What is Regeneron Pharmaceuticals, Inc.'s profit margin?
Regeneron Pharmaceuticals, Inc. has a net profit margin of 27.9%, which is considered high and reflects strong pricing power. Its gross margin stands at 44.5%, indicating a high-margin business model.
What is REGN's dividend yield?
Regeneron Pharmaceuticals, Inc. currently offers a dividend yield of 0.45%, a modest payout typical for growth-oriented companies. Dividend yields can change based on price movements and company payout decisions.
Is Regeneron Pharmaceuticals, Inc.'s revenue growing?
Regeneron Pharmaceuticals, Inc. is reporting solid revenue growth of 16.7% year-over-year. However, earnings declined 4.5%, which warrants monitoring.
How much debt does Regeneron Pharmaceuticals, Inc. have?
Regeneron Pharmaceuticals, Inc. has a debt-to-equity ratio of 0.09×, reflecting a very low debt-to-equity ratio, signalling a conservatively financed balance sheet. Its current ratio is 3.33×, indicating comfortable short-term liquidity.
Compare REGN with any stock